Cargando…

Psychotropic medication for challenging behavior in people with learning disabilities in Qatar

INTRODUCTION: Challenging behavior is a common reason for referral to psychiatric service. Psychotropic medications widely used to modify behaviors, even when no evidence of diagnosable mental illness. However, literature show little evidence that benefits outweigh the risks in their prescription. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Eltorki, Y., Tahir, M. El, Husein, B. El, Abdallah, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479826/
http://dx.doi.org/10.1192/j.eurpsy.2021.1910
_version_ 1784790880233717760
author Eltorki, Y.
Tahir, M. El
Husein, B. El
Abdallah, O.
author_facet Eltorki, Y.
Tahir, M. El
Husein, B. El
Abdallah, O.
author_sort Eltorki, Y.
collection PubMed
description INTRODUCTION: Challenging behavior is a common reason for referral to psychiatric service. Psychotropic medications widely used to modify behaviors, even when no evidence of diagnosable mental illness. However, literature show little evidence that benefits outweigh the risks in their prescription. Monitoring using International guidelines may help improving the outcomes. We audit current practice against known standards. OBJECTIVES: - To assess adherence within the Qatar Mental Health Services to National guidelines on using medication to manage behavior problems in adults with a learning disability. - To identify strengths and weaknesses in current practice. - To Make recommendations to improve LD patient care METHODS: Patients with LD attending psychiatric clinic screened using selection and exclusion criteria and data collected and analyzed using format from the International standards. RESULTS: 102 patients screened, 85 selected and 17 cases excluded Age range 18 to 50 years. 27% mild, 29% moderate and 44% severe LD, Autism 40% Psychiatric Diagnosis 55% Challenging behavior 45% Antipsychotic prescribing: 79% Rationale documented in 74%, Capacity assessment in 81%, Review of side effects in 53% Safety of medication in 61%, Medication discontinuation in 66%, Reasons for discontinuation in 36% CONCLUSIONS: Antipsychotics use (79%) is high with several combinations of IM and oral or more than 2 drugs. There is need for improvement across all standards. Rationalising the prescribing for LD patients to improve the outcomes for the safety of these patients. The audit indicate need for specialist service to monitor prescribing and apply standards of care in clinical service. DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9479826
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-94798262022-09-29 Psychotropic medication for challenging behavior in people with learning disabilities in Qatar Eltorki, Y. Tahir, M. El Husein, B. El Abdallah, O. Eur Psychiatry Abstract INTRODUCTION: Challenging behavior is a common reason for referral to psychiatric service. Psychotropic medications widely used to modify behaviors, even when no evidence of diagnosable mental illness. However, literature show little evidence that benefits outweigh the risks in their prescription. Monitoring using International guidelines may help improving the outcomes. We audit current practice against known standards. OBJECTIVES: - To assess adherence within the Qatar Mental Health Services to National guidelines on using medication to manage behavior problems in adults with a learning disability. - To identify strengths and weaknesses in current practice. - To Make recommendations to improve LD patient care METHODS: Patients with LD attending psychiatric clinic screened using selection and exclusion criteria and data collected and analyzed using format from the International standards. RESULTS: 102 patients screened, 85 selected and 17 cases excluded Age range 18 to 50 years. 27% mild, 29% moderate and 44% severe LD, Autism 40% Psychiatric Diagnosis 55% Challenging behavior 45% Antipsychotic prescribing: 79% Rationale documented in 74%, Capacity assessment in 81%, Review of side effects in 53% Safety of medication in 61%, Medication discontinuation in 66%, Reasons for discontinuation in 36% CONCLUSIONS: Antipsychotics use (79%) is high with several combinations of IM and oral or more than 2 drugs. There is need for improvement across all standards. Rationalising the prescribing for LD patients to improve the outcomes for the safety of these patients. The audit indicate need for specialist service to monitor prescribing and apply standards of care in clinical service. DISCLOSURE: No significant relationships. Cambridge University Press 2021-08-13 /pmc/articles/PMC9479826/ http://dx.doi.org/10.1192/j.eurpsy.2021.1910 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Eltorki, Y.
Tahir, M. El
Husein, B. El
Abdallah, O.
Psychotropic medication for challenging behavior in people with learning disabilities in Qatar
title Psychotropic medication for challenging behavior in people with learning disabilities in Qatar
title_full Psychotropic medication for challenging behavior in people with learning disabilities in Qatar
title_fullStr Psychotropic medication for challenging behavior in people with learning disabilities in Qatar
title_full_unstemmed Psychotropic medication for challenging behavior in people with learning disabilities in Qatar
title_short Psychotropic medication for challenging behavior in people with learning disabilities in Qatar
title_sort psychotropic medication for challenging behavior in people with learning disabilities in qatar
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479826/
http://dx.doi.org/10.1192/j.eurpsy.2021.1910
work_keys_str_mv AT eltorkiy psychotropicmedicationforchallengingbehaviorinpeoplewithlearningdisabilitiesinqatar
AT tahirmel psychotropicmedicationforchallengingbehaviorinpeoplewithlearningdisabilitiesinqatar
AT huseinbel psychotropicmedicationforchallengingbehaviorinpeoplewithlearningdisabilitiesinqatar
AT abdallaho psychotropicmedicationforchallengingbehaviorinpeoplewithlearningdisabilitiesinqatar